ICYMI in #sicklecelldisease on #Heme Today: Analysis from Akshay Sharma MD of St. Jude, and colleagues, found exa-cel improves QoL in severe #SCD, eliminates #vasoocclusivecrisis in a vast majority of pts. #VOC buff.ly/NZ2MRyC

In #hemophilia tx development news on #Heme Today---Novo Nordisk submits BLA to U.S. FDA for denecimig in HA with/without prior factor VIII inhibitors: buff.ly/81pFsVe

On #Heme Today, new findings in pediatric #hemophilia: In pts who have untreated severe HA with high-titer #factorVIIIinhibitors, researchers find predictors for success of the first course of immune tolerance induction. buff.ly/7WkS0EZ

As we inch closer to #ESMO25 and #ASH25, let's reflect on #ASCO25 and the groundbreaking research that's redefining standards of care, from targeted therapies to novel immunotherapies. ➡️ buff.ly/oY2EqwC

Encouraging study survival results reported for azacitidine plus ruxolitinib in pts with accelerated or blast phase #myeloproliferativeneoplasm ineligible for intensive chemotherapy or transplant. #MPN, #Heme buff.ly/WoqTsF6

Did you miss our quiz on #Heme Today's clinical news coverage of #SickleCellAwarenessMonth? Take it now! #sicklecelldisease, #SCD, #sicklecell buff.ly/DBSoGoC

On #Heme Today: Investigators led by Josu de la Fuente of Imperial NHS 💙 found exa-cel benefits health-related QoL in adult, adolescent pts with #transfusiondependent #betathalassemia. buff.ly/82sdKIF

Recap from the week in tx development news on #Heme Today---Novo Nordisk has submitted a BLA to U.S. FDA for denecimig in #hemophilia A, with or without prior factor VIII inhibitors: buff.ly/81pFsVe

In light of the NIH’s initiative to reduce funding for animal studies, computational models and organoids offer new research pathways. Read more from our latest feature, with insight from Drs. Dr. Len Zon and Kellie Machlus of Boston Children's. 📖 buff.ly/ZmVQG6i

An encouraging set of results data is reported by Davide Matino, MD, of McMaster University, and colleagues, from the ongoing phase 3 BASIS trial of marstacimab for #hemophilia A, B, with or without inhibitors. #Heme buff.ly/3B6TqRZ

As the American Red Cross has alerted, US hospitals face a shortage of critical blood supplies, an issue especially serious for pts with conditions such as #sicklecelldisease, beta-#thalassemia, or cancer. #Heme buff.ly/ZnVHLJY

On #Heme Today: An analysis of 3 clinical trials by Manuel Carcao, MD, MSc, of The Hospital for Sick Children (SickKids), and colleagues, points to a safe dose level for eptacog beta in #hemophilia A, B. buff.ly/vLyA7em

ICYMI in #myeloproliferativeneoplasm coverage on #Heme Today: Encouraging study survival results reported for azacitidine plus ruxolitinib in pts with accelerated or #blastphase #MPN ineligible for intensive chemotherapy or transplant. buff.ly/WoqTsF6

Today is the first day of #ESMO25! From isatuximab in #myeloma to tafasitamab in #DLBCL, stay up to date on the latest drug developments being presented this weekend. Which session or presentation are you looking forward to the most? ➡️ buff.ly/rhlBjaX

In regulatory news on #Heme Today: U.S. FDA approves expanded indications in #vonWillebranddisease for VONVENDI, a recombinant von Willebrand factor product from Takeda. #VWD buff.ly/HvcVwK5

In pediatric pts with untreated severe #hemophilia A, high-titer #factorVIIIinhibitors, researchers have found predictors for success of a first course of immune tolerance induction. #Heme buff.ly/EvknhWM

A look back in the week on #Heme Today: Promising results data were reported by Davide Matino, MD, of McMaster University, and colleagues, from an ongoing phase 3 trial of marstacimab for #hemophilia A, B. buff.ly/3B6TqRZ

Reporting on #Heme Today ---The information resources ASH makes available to hematology clinicians, researchers seeking NIH funding: buff.ly/Y1lDa40

Our October print issue is out now! 🎃🎉 This issue includes a feature on the shifting role of animal studies in blood cancers, a look into the University of Colorado Anschutz research labs, commentary from BCT columnist Kimberly Ku, and more! ➡️ buff.ly/vewa5o2

In the SELECT-MDS-1 trial, addition of tamibarotene to azacitidine yielded disappointing results in higher-risk #myelodysplasticsyndromes with RARα overexpression. #MDS, #Heme buff.ly/t3rRaCG